Eli Lilly (LLY) Short-Term Debt issuances (2009 - 2026)

Eli Lilly has reported Short-Term Debt issuances for 17 years, with the latest figure at $1.8 billion in Q1 2026.

• For the quarter ending Q1 2026, Short-Term Debt issuances rose 196.0% year-over-year to $1.8 billion; the trailing twelve-month figure through Mar 2026 stood at -$714.0 million (down 147.48% YoY), and the FY2025 full-year result was -$4.3 billion, down 134.23% from the prior year.
• Short-Term Debt issuances for Q1 2026 stood at $1.8 billion, up from -$400000.0 in the prior quarter.
• The five-year high for Short-Term Debt issuances was $4.6 billion in Q4 2023, with the low at -$5.2 billion in Q1 2024.
• Historically, Short-Term Debt issuances has averaged $110.9 million across 5 years, with a median of $249.6 million in 2022.
• Annual changes were most pronounced in 2022 — Short-Term Debt issuances slumped 9632.0% — and 2023, when it surged 1988.2%.
• Eli Lilly's Short-Term Debt issuances stood at -$243.3 million in 2022, then surged by 1988.2% to $4.6 billion in 2023, then sank by 33.78% to $3.0 billion in 2024, then tumbled by 100.01% to -$400000.0 in 2025, then soared by 443850.0% to $1.8 billion in 2026.
• The last three Short-Term Debt issuances figures came in at $1.8 billion (Q1 2026), -$400000.0 (Q4 2025), and -$4.1 billion (Q3 2025), per Business Quant data.